Search Within

Raphael Eric Steiner

Formats
  1. Meeting Abstract (14)
  2. Journal Article (4)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (17)
  2. Department of Medicine (17)
  3. Hematologic Malignancies, Division of (17)
  4. Lymphoma (17)
  5. Hematology-Oncology Fellows (15)
  6. Weinberg Fellows (15)

More Groups

People
  1. Ariela Noy (15)
  2. Alison Moskowitz (14)
  3. Anita Kumar (14)
  4. Gilles Salles (14)
  5. Lorenzo Falchi (14)
  6. Maria Palomba (14)

More People

Years
  1. 2025 (2)
  2. 2024 (17)
Publications
  1. Blood (14)
  2. Blood Cancer Journal (1)
  3. JAMA Oncology (1)
  4. Journal of Clinical Oncology (1)
  5. Leukemia and Lymphoma (1)
  6. eClinicalMedicine (1)
Publishers
  1. American Society of Hematology (14)
  2. American Medical Association (1)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Inc. (1)
  5. Nature Publishing Group (1)
  6. Taylor & Francis Group (1)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improving outcomes in plasmablastic lymphoma: A multicenter experience from an American cohort
    Meeting Abstract

    Hamby, M.; Egleston, B.; Frosch, Z. A. K.; Steiner, R. E.; Noy, A.; Carvajal, V.; Tolu, S. S.; Jean-Louis, G.; Amengual, J. E.; Patel, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Response-adapted ultralow-dose radiation therapy for orbital indolent B-cell lymphoma: A phase 2 nonrandomized controlled trial
    Journal Article

    Pinnix, C. C.; Dabaja, B. S.; Gunther, J. R.; Fang, P. Q.; Wu, S. Y.; Nastoupil, L. J.; Strati, P.; Nair, R.; Ahmed, S.; Steiner, R.; more...
    JAMA Oncology (2024)

    Fulltext@MSK | Save
  • Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: A single group, open-label, phase 1/2 trial
    Journal Article

    Gurumurthi, A.; Chin, C. K.; Feng, L.; Fowler, N. H.; Strati, P.; Hagemeister, F. B.; Fayad, L. E.; Westin, J. R.; Obi, C.; Arafat, J.; more...
    eClinicalMedicine (2024)

    Fulltext@MSK | Save